eng Oriental Scientific Publishing Company Biomedical and Pharmacology Journal 0974-6242 2026-03-20 19 1 642 652 10.13005/bpj/3381 70168 article Zafar Isomiddinovich Sanoev 1 Sokhib Zamon ogli Rashidov 1 Tolmas Tolibovich Khamroev 1 Ibrokhimjon Tuychievich Abdinazarov 1 Sukhrob Davlatyor ogli Rakhimboev 2 Dilnoza Safaralievna Ismailova 3 Department of Pharmacology and Toxicology of the Institute of Chemistry of Plant Substances named after Academician S.Y. Yunusov of the Academy of Sciences of the Republic of Uzbekistan, Uzbekistan Department of Biomedical Sciences, Faculty of Medicine of Kimyo international university in Tashkent, Uzbekistan Department of Organic Synthesis of the Institute of Chemistry of Plant Substances named after Academician S.Y. Yunusov of the Academy of Sciences of the Republic of Uzbekistan, Uzbekistan Department of Pharmacology of Tashkent State Medical University. Uzbekistan Profi University, Bektemir dist, Tashkent, Uzbekistan Many psychiatrists have consistently pointed out the link between stressors and the emergence of depressed moods.  Both acute traumatic experiences and long-term psychogenic stress can contribute to the development of depressive disorders in people. The aim of this research is to develop a novel antidepressant medication based on compound-1, 5-(2-aminophenyl)-1,3,4-oxadiazole-2-(3H)-thione. The reference medication fluoxetine and 5-(2-aminophenyl)-1,3,4-oksadiazole-2(3H)-thione (compound 1) were the subjects of the investigation. Their effects were evaluated using models such as the FST and TST, which measure behavioral despair and immobility in response to stress. Other factors that were assessed included acute toxicity, locomotor activity, research activities, anti-anxiety activity, and the spectrum of antidepressant action.  In all studies, chemical 1 was administered orally at dosages of 0.1, 0.5, 1.0, 5.0, 10.0, 30.0, and 60.0 mg/kg. Experiments conducted on models of stress-induced depression revealed that compound-1 has a strong antidepressant effect when given once to mice (male and female).  Under compound-1's influence, the animals' total immobilization time decreased and the latency period before the onset of immobility increased statistically substantially in the "non-escapable forced Porsolt swimming" and "hanging mice by the tail" tests.  Under the effect of the test drug, the number of jumps made by the animals and the total amount of time spent actively swimming increased statistically considerably in the "non-escapable forced swimming, but Porsolt" test. The uniqueness and benefits of compound-1 as a possible antidepressant medication have therefore been demonstrated by neuro- and psychopharmacological research comparing it to the well-known antidepressant fluoxetine. https://biomedpharmajournal.org/vol19no1/synthesis-and-antidepressant-activity-of-5-2-aminophenyl-134-oxadiazole-2-3h-thione/ Depression models Depressive states Forced swim test Fluoxetine Immobilization Tail suspension test